Tempest Therapeutics (NASDAQ:TPST) Trading Down 4.6% – Here’s What Happened

Tempest Therapeutics, Inc. (NASDAQ:TPST) shares fell 4.6% during mid-day trading on Thursday . The stock traded as low as $2.28 and last traded at $2.29. 61,761 shares were traded during trading, a decline of 23% from the average session volume of 80,506 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tempest Therapeutics has a consensus rating of “Reduce” and an average price target of $12.50.

Tempest Therapeutics Stock Performance

The stock has a market cap of $11.29 million, a PE ratio of -0.23 and a beta of -2.42. The stock has a fifty day moving average price of $2.54 and a 200 day moving average price of $5.99.

Hedge Funds Weigh In On Tempest Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Sabby Management LLC purchased a new stake in Tempest Therapeutics in the 4th quarter worth about $513,000. Dimensional Fund Advisors LP bought a new position in shares of Tempest Therapeutics during the fourth quarter valued at approximately $33,000. Finally, Vanguard Group Inc. raised its holdings in shares of Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after buying an additional 27,952 shares during the period. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.